Company intelligence / Profile preview
Ichor Medical Systems
- Ownership
- Private
- Development stage
- Phase 1
Overview
Ichor Medical Systems develops the TriGrid® Delivery System—an integrated and automated electroporation device that enhances intracellular delivery of nucleic acids for vaccines and therapeutics. The technology has been clinically tested and used in multiple partnered programs targeting infectious diseases such as COVID‑19, HBV, HIV; cancer immunotherapy; and biodefense agents. Some programs have advanced to Phase II clinical trials.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- DNA vaccinesNucleic acid-based drugs (including mRNA and DNA)Monoclonal antibodies (via nucleic acid delivery)Protein therapeutics (via nucleic acid delivery)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Ichor Medical Systems.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ichor Medical Systems.